Future growth expectations in sales/revenue/volumes?

The company targets over 30% growth in revenue for the financial year, aiming to reach approximately INR 65 crores from INR 50 crores last year. Q1 revenue grew by 8-9% year-on-year, with domestic sales rising significantly by 17%. Export business showed marginal growth (~2%) due to global recession and foreign exchange challenges but is expected to improve with expansion in markets like USA, Australia, Canada, and Brazil. Capacity utilization currently at 40% with sufficient capacity to operate for the next five years without additional capital expenditure. New product lines, including oral h

Any current/future new fundraising through debt or equity?

No direct mention of any current or planned fundraising through debt or equity in the transcript. The company has recently raised funds through an IPO, which was used for capital expenditure on R&D facilities and new plant and machinery. Promoters have foregone the final dividend to support strategic investments, indicating internal funding preference. Future investments are expected to be funded from internal accruals and existing resources. No explicit plans shared about raising fresh debt or equity in the near term during the call.

Any current/future capex/capital investment/strategic investment?

The company has capital work in progress (CWIP) of about INR17.87 crores related to expansion and R&D facilities. Total investment in R&D and new facility is around INR35 crores, with INR17.7 crores spent on capital expenditure; INR7 crores on R&D and INR10 crores on new facility. Remaining investment includes land, building, and durables funded internally. Some funds are reserved for marketing expenditures to be utilized over the next couple of years. The new capacity expansion includes upgraded existing facilities and separate new facilities for oral hygiene and biomaterial products. Current

Future growth expectations in earnings/operating earnings/profits/EPS?

Prevest DenPro expects to maintain a strong growth trajectory with over 30% revenue growth targeted for FY24, building on past growth of over 30% in recent years. Q1 FY24 saw 8% revenue growth (INR14 crores) and 11% PAT growth (INR4.08 crores) compared to the previous year. EBITDA margin was steady at around 40%, with PAT margin at 29%, reflecting strong profitability and efficient cost management. Management is optimistic about accelerated domestic market growth to offset export challenges caused by global recession and foreign exchange issues. New product development and market expansion eff

Prevest DenproQ1 FY24Healthcare Equipment & Supplies

Prevest Denpro Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹405P/E: 21.6Market Cap: ₹486 CrSector: Healthcare Equipment & Supplies

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

The company targets over 30% growth in revenue for the financial year, aiming to reach approximately INR 65 crores from INR 50 crores last year.
Q1 revenue grew by 8-9% year-on-year, with domestic sales rising significantly by 17%.
Export business showed marginal growth (~2%) due to global recession and foreign exchange challenges but is expected to improve with expansion in markets like USA, Australia, Canada, and Brazil.
Capacity utilization currently at 40% with sufficient capacity to operate for the next five years without additional capital expenditure.
New product lines, including oral hygiene and biomaterials, are in development and expected to contribute to growth.
Import substitution products may save about INR 1 crore annually.
3D printing regime projected to generate INR 2-2.5 crores turnover over the next two years.
Decentralized and professionalized marketing to accelerate domestic growth further.

Margin guidance

Category 3

Prevest DenPro expects to maintain a strong growth trajectory with over 30% revenue growth targeted for FY24, building on past growth of over 30% in recent years.
Q1 FY24 saw 8% revenue growth (INR14 crores) and 11% PAT growth (INR4.08 crores) compared to the previous year.
EBITDA margin was steady at around 40%, with PAT margin at 29%, reflecting strong profitability and efficient cost management.
Management is optimistic about accelerated domestic market growth to offset export challenges caused by global recession and foreign exchange issues.
New product development and market expansion efforts, including a decentralized sales approach and focus on emerging international markets (e.g., USA, Australia, Canada, Brazil), are expected to drive sustainable long-term growth.
Import substitution and 3D printing segments are projected to add incremental revenue and cost savings (e.g., INR1 crore annual cost saving from import substitution, INR2-2.5 crore turnover from 3D printing in 2 years).
Dividend payout may be moderated due to strategic investment focus on R&D and marketing for future growth.

See what Prevest Denpro management said on margin guidance — free account, 30 seconds.

Fundraise plans

No direct mention of any current or planned fundraising through debt or equity in the transcript.
The company has recently raised funds through an IPO, which was used for capital expenditure on R&D facilities and new plant and machinery.
Promoters have foregone the final dividend to support strategic investments, indicating internal funding preference.
Future investments are expected to be funded from internal accruals and existing resources.
No explicit plans shared about raising fresh debt or equity in the near term during the call.

Order book

The transcript does not explicitly mention details about the current or expected order book or pending orders for Prevest DenPro Limited. However, the following relevant points provide some context about the company's business outlook: - The company has experienced growth in domestic sales and added seven new dealers recently, indicating an expanding demand pipeline. - Despite a global recession affecting exports, management is optimistic about accelerated domestic growth. - Capacity utilization is currently at 40% on a single shift basis, with capacity sufficient for the next five years without additional capital expenditure, enabling the fulfillment of future orders. - New facilities and products in the oral hygiene and medical segment are expected to contribute additional turnover (INR 2–2.5 crores from 3D printing in next two years). No explicit or quantified data on the current order book or pending orders was disclosed in the transcript.

See what Prevest Denpro management said on order book — free account, 30 seconds.

Capex plans

Yes

The company has capital work in progress (CWIP) of about INR17.87 crores related to expansion and R&D facilities.
Total investment in R&D and new facility is around INR35 crores, with INR17.7 crores spent on capital expenditure; INR7 crores on R&D and INR10 crores on new facility.
Remaining investment includes land, building, and durables funded internally.
Some funds are reserved for marketing expenditures to be utilized over the next couple of years.
The new capacity expansion includes upgraded existing facilities and separate new facilities for oral hygiene and biomaterial products.
Current capacity utilization is 40% with enough capacity to operate for the next five years without further capex.
A cost saving of about INR1 crore is expected from import substitution initiatives under development.
The company is investing strategically in new product lines, import substitution, and marketing to sustain growth.

Track Prevest Denpro — get its next earnings analysis in your feed

How does Prevest Denpro rank vs peers in Healthcare Equipment & Supplies?

Pro feature

ThisPrevest Denpro

Rev 2Mar 3

See where Prevest Denpro sits in Healthcare Equipment & SuppliesSee which companies these are, and every other name in the sector.Open rankings

How does Prevest Denpro rank in Healthcare Equipment & Supplies?

Compare Prevest Denpro against every Healthcare Equipment & Supplies company (Q1 FY24) on revenue, margins and earnings-call signals.

View Healthcare Equipment & Supplies leaderboard →

What Prevest Denpro's management said in earlier quarters

Others in Healthcare Equipment & Supplies this season

Aprameya Enginee (Q2 FY26)
H1FY26 Revenue from Operations: Rs 421.4 Mn, up 343% YoY from Rs 92.7 Mn in H1FY25. Key investor presentation takeaways from Aprameya Engineering Ltd's Q2 FY26
QMS Medical Allied Services Ltd (Q3 FY26)
Q3FY26 Revenue from Operations: ₹37.3 crore . Key investor presentation takeaways from QMS Medical Allied Services Ltd's Q3 FY26 investor presentation — and how
Vaidya Sane (Q4 FY26)
170-180 crores driven by higher patient additions, increased hospital utilization, and franchise clinic growth. Key concall takeaways from Vaidya Sane Ayurved…
Avience Biomedicals Ltd (Q1 FY27)
New manufacturing facility has capacity to support peak revenue of around ₹250–265 crore, subject to product mix and approvals. Key concall takeaways from…

Compare:vs Molbio Diagnosti vs Poly Medicure Ltd vs Laxmi Dental Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →